A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Exclusion Criteria

• •Primary failure (no response within 12 weeks) to 1 or more interleukin-17 (IL-17) biologic response modifiers (eg, brodalumab, ixekizumab, secukinumab) OR more than 1 biologic response modifier other than an IL-17
• •Study participant has a presence of guttate, inverse, pustular, or erythrodermic PSO or other dermatological condition that may impact the clinical assessment of PSO
• •Study participant has a history of inflammatory bowel disease (IBD) or symptoms suggestive of IBD
• •History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated
• •Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)
• •Study participant has previously received bimekizumab
• •Study participant has previously received ustekinumab
• •Study participant has received drugs outside the specified timeframes relative to the Baseline Visit or receives prohibited concomitant treatments
• •Study participant has the presence of active suicidal ideation, or positive suicide behavior
• •Study participant diagnosed with severe depression in the past 6 months (prior to Screening) should be excluded
• •Study participant has a history of psychiatric inpatient hospitalization within the past year before enrolling into the study